192 related articles for article (PubMed ID: 17854396)
1. Molecular characteristics in papillary thyroid cancers (PTCs) with no 131I uptake.
Mian C; Barollo S; Pennelli G; Pavan N; Rugge M; Pelizzo MR; Mazzarotto R; Casara D; Nacamulli D; Mantero F; Opocher G; Busnardo B; Girelli ME
Clin Endocrinol (Oxf); 2008 Jan; 68(1):108-16. PubMed ID: 17854396
[TBL] [Abstract][Full Text] [Related]
2. BRAF V600E and decreased NIS and TPO expression are associated with aggressiveness of a subgroup of papillary thyroid microcarcinoma.
Bastos AU; Oler G; Nozima BH; Moysés RA; Cerutti JM
Eur J Endocrinol; 2015 Oct; 173(4):525-40. PubMed ID: 26338373
[TBL] [Abstract][Full Text] [Related]
3. BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism.
Durante C; Puxeddu E; Ferretti E; Morisi R; Moretti S; Bruno R; Barbi F; Avenia N; Scipioni A; Verrienti A; Tosi E; Cavaliere A; Gulino A; Filetti S; Russo D
J Clin Endocrinol Metab; 2007 Jul; 92(7):2840-3. PubMed ID: 17488796
[TBL] [Abstract][Full Text] [Related]
4. Expression of iodine metabolism genes in human thyroid tissues: evidence for age and BRAFV600E mutation dependency.
Espadinha C; Santos JR; Sobrinho LG; Bugalho MJ
Clin Endocrinol (Oxf); 2009 Apr; 70(4):629-35. PubMed ID: 18710471
[TBL] [Abstract][Full Text] [Related]
5. BRAFV600E mutation, but not RET/PTC rearrangements, is correlated with a lower expression of both thyroperoxidase and sodium iodide symporter genes in papillary thyroid cancer.
Romei C; Ciampi R; Faviana P; Agate L; Molinaro E; Bottici V; Basolo F; Miccoli P; Pacini F; Pinchera A; Elisei R
Endocr Relat Cancer; 2008 Jun; 15(2):511-20. PubMed ID: 18509003
[TBL] [Abstract][Full Text] [Related]
6. Prognostic prediction of BRAF(V600E) and its relationship with sodium iodide symporter in classic variant of papillary thyroid carcinomas.
Gao WL; Wie LL; Chao YG; Wie L; Song TL
Clin Lab; 2012; 58(9-10):919-26. PubMed ID: 23163107
[TBL] [Abstract][Full Text] [Related]
7. BRAF in primary and recurrent papillary thyroid cancers: the relationship with (131)I and 2-[(18)F]fluoro-2-deoxy-D-glucose uptake ability.
Barollo S; Pennelli G; Vianello F; Watutantrige Fernando S; Negro I; Merante Boschin I; Pelizzo MR; Rugge M; Mantero F; Nacamulli D; Girelli ME; Busnardo B; Mian C
Eur J Endocrinol; 2010 Oct; 163(4):659-63. PubMed ID: 20647301
[TBL] [Abstract][Full Text] [Related]
8. mRNA Expression of SLC5A5 and SLC2A Family Genes in Papillary Thyroid Cancer: An Analysis of The Cancer Genome Atlas.
Suh S; Kim YH; Goh TS; Jeong DC; Lee CS; Jang JY; Cha W; Han ME; Kim SJ; Kim IJ; Pak K
Yonsei Med J; 2018 Aug; 59(6):746-753. PubMed ID: 29978611
[TBL] [Abstract][Full Text] [Related]
9. Effects of BRAF(V600E) mutation on Na(+)/I(-) symporter expression in papillary thyroid carcinoma.
Dong H; Shen WZ; Yan YJ; Yi JL; Zhang L
J Huazhong Univ Sci Technolog Med Sci; 2016 Feb; 36(1):77-81. PubMed ID: 26838744
[TBL] [Abstract][Full Text] [Related]
10. Relationships between transporter expression and the status of BRAF V600E mutation and F-18 FDG uptake in papillary thyroid carcinomas.
Yoon M; Jung SJ; Kim TH; Ha TK; Urm SH; Park JS; Lee SM; Bae SK
Endocr Res; 2016; 41(1):64-9. PubMed ID: 26513490
[TBL] [Abstract][Full Text] [Related]
11. Reduced expression of THRβ in papillary thyroid carcinomas: relationship with BRAF mutation, aggressiveness and miR expression.
Rosignolo F; Maggisano V; Sponziello M; Celano M; Di Gioia CR; D'Agostino M; Giacomelli L; Verrienti A; Dima M; Pecce V; Durante C
J Endocrinol Invest; 2015 Dec; 38(12):1283-9. PubMed ID: 26003825
[TBL] [Abstract][Full Text] [Related]
12. Clinical Manifestations and Gene Expression in Patients with Conventional Papillary Thyroid Carcinoma Carrying the BRAF(V600E) Mutation and BRAF Pseudogene.
Lin JD; Fu SS; Chen JY; Lee CH; Chau WK; Cheng CW; Wang YH; Lin YF; Fang WF; Tang KT
Thyroid; 2016 May; 26(5):691-704. PubMed ID: 26914762
[TBL] [Abstract][Full Text] [Related]
13. Dual inhibition of BRAF and MEK increases expression of sodium iodide symporter in patient-derived papillary thyroid cancer cells in vitro.
Ullmann TM; Liang H; Moore MD; Al-Jamed I; Gray KD; Limberg J; Stefanova D; Buicko JL; Finnerty B; Beninato T; Zarnegar R; Min IM; Fahey TJ
Surgery; 2020 Jan; 167(1):56-63. PubMed ID: 31585718
[TBL] [Abstract][Full Text] [Related]
14. Role and relevance of BRAF mutations in risk stratifying patients of papillary thyroid cancers along with a review of literature.
Krishnamurthy A; Ramshankar V; Murherkar K; Vidyarani S; Raghunandhan GC; Das A; Desai PB; Albert K
Indian J Cancer; 2017; 54(1):372-378. PubMed ID: 29199726
[TBL] [Abstract][Full Text] [Related]
15. The correlation of sodium iodide symporter and BRAF(V600E) mutation in classical variant papillary thyroid carcinoma.
Yazgan A; Yıldırım N; Gözalan A; Gümüştaş S; Kılıçarslan A; Balci S; Aydın C; Ersoy R; Cakir B; Güler G
Ann Diagn Pathol; 2016 Jun; 22():58-62. PubMed ID: 27180062
[TBL] [Abstract][Full Text] [Related]
16. Increase in Papillary Thyroid Cancer Incidence Is Accompanied by Changes in the Frequency of the BRAF V600E Mutation: A Single-Institution Study.
Kowalska A; Walczyk A; Kowalik A; Pałyga I; Trybek T; Kopczyński J; Kajor M; Chrapek M; Pięciak L; Chłopek M; Góźdź S; Kamiński G
Thyroid; 2016 Apr; 26(4):543-51. PubMed ID: 26889698
[TBL] [Abstract][Full Text] [Related]
17. Expression of the Na+/I- symporter gene in human thyroid tumors: a comparison study with other thyroid-specific genes.
Lazar V; Bidart JM; Caillou B; Mahé C; Lacroix L; Filetti S; Schlumberger M
J Clin Endocrinol Metab; 1999 Sep; 84(9):3228-34. PubMed ID: 10487692
[TBL] [Abstract][Full Text] [Related]
18. Expression pattern of the pendrin and sodium/iodide symporter genes in human thyroid carcinoma cell lines and human thyroid tumors.
Arturi F; Russo D; Bidart JM; Scarpelli D; Schlumberger M; Filetti S
Eur J Endocrinol; 2001 Aug; 145(2):129-35. PubMed ID: 11454507
[TBL] [Abstract][Full Text] [Related]
19. BRAF mutation associated with other genetic events identifies a subset of aggressive papillary thyroid carcinoma.
Costa AM; Herrero A; Fresno MF; Heymann J; Alvarez JA; Cameselle-Teijeiro J; García-Rostán G
Clin Endocrinol (Oxf); 2008 Apr; 68(4):618-34. PubMed ID: 18070147
[TBL] [Abstract][Full Text] [Related]
20. The BRAFV600E oncogene induces transforming growth factor beta secretion leading to sodium iodide symporter repression and increased malignancy in thyroid cancer.
Riesco-Eizaguirre G; Rodríguez I; De la Vieja A; Costamagna E; Carrasco N; Nistal M; Santisteban P
Cancer Res; 2009 Nov; 69(21):8317-25. PubMed ID: 19861538
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
